37 results on '"Yagüe B"'
Search Results
2. Estudio descriptivo de las infecciones asociadas con instrumentación de columna en un hospital terciario
- Author
-
Rico Nieto, A., Loeches Yagüe, B., Quiles Melero, I., Talavera Buedo, G., Pizones, J., and Fernández-Baillo Sacristana, N.
- Published
- 2024
- Full Text
- View/download PDF
3. Dalbavancin as Consolidation Therapy in Elderly Patients
- Author
-
Sastre, Lucia Corral, primary, AC, Gallotti, additional, Yagüe B, Loeches, additional, F, Moreno Ramos, additional, and A, Rico Nieto, additional
- Published
- 2023
- Full Text
- View/download PDF
4. Dalbavancin as Consolidation Therapy in Elderly Patients
- Author
-
Lucia Corral Sastre, Gallotti AC, Loeches Yagüe B, Moreno Ramos F, and Rico Nieto A
- Subjects
General Medicine - Published
- 2023
- Full Text
- View/download PDF
5. 20912. ¿MELOMANÍA O ALUCINACIÓN? UN CÓDIGO ICTUS INHABITUAL
- Author
-
de la Puente Garrido, B., Velasco Calvo, R., Gómez-Porro Sánchez, P., Escamilla Crespo, C., Trebolle Banet, J., Bárez Sagasti, F., Barrios Álamo, L., Barrios Álamo, C., and Abarrategui Yagüe, B.
- Published
- 2024
- Full Text
- View/download PDF
6. 20492. EPILEPSIA MIOCLÓNICA DE DEBUT TARDÍO: ¿“JUVENIL” EN UN ANCIANO?
- Author
-
Bárez Sagasti, F., Hernán Gómez, R., Abarrategui Yagüe, B., de la Puente Garrido, B., Barrios Álamo, L., Barrios Álamo, C., Ebrat Mancilla, E., and Marín Serrano, M.
- Published
- 2024
- Full Text
- View/download PDF
7. 20859. ESTATUS DE AUSENCIA COMO DEBUT TARDÍO DE EPILEPSIA GENERALIZADA
- Author
-
Barrios Álamo, L., Gómez Dunlop, M., Huimann, P., Martín de la Morena, C., Barrios Álamo, C., Martín Mañueco, L., Ebrat Mancilla, E., García Fleitas, B., Gómez-Porro Sánchez, P., and Abarrategui Yagüe, B.
- Published
- 2024
- Full Text
- View/download PDF
8. PO-1260: 30-Day Mortality Following Palliative Radiotherapy
- Author
-
Vázquez Varela, M., primary, Altabas Gonzalez, M., additional, Giraldo Marín, A., additional, Reyes López, V., additional, Maldonado Pijoan, X., additional, Navalpotro Yagüe, B., additional, Ramos Albiac, M., additional, Vergés Capdevila, R., additional, Benavente Norza, S., additional, Micó Milla, S., additional, Granado Carrasco, R., additional, and Giralt López de Sagredo, J., additional
- Published
- 2020
- Full Text
- View/download PDF
9. Lymphocytic meningitis and spinal neurocysticercosis: A case report and literature review
- Author
-
Abarrategui Yagüe, B., García García, M.E., Orviz García, A., and Casas Limón, J.
- Published
- 2014
- Full Text
- View/download PDF
10. Meningitis linfocitaria y neurocisticercosis espinal. A propósito de un caso y revisión de la literatura
- Author
-
Abarrategui Yagüe, B., García García, M.E., Orviz García, A., and Casas Limón, J.
- Published
- 2014
- Full Text
- View/download PDF
11. Guardamos la lengua. Editorial
- Author
-
Tolosa Montesinos, Juan, Yagüe Barredo, Agustín, Díaz Rodríguez, Lourdes, and Real Espinosa, Juan Manuel
- Subjects
Language and Literature - Abstract
Editorial
- Published
- 2023
12. Hojas de información para el paciente en atención primaria
- Author
-
Loeches Yagüe, B, primary and Lorenzo-Cáceres Ascanio, A de, additional
- Published
- 2004
- Full Text
- View/download PDF
13. Phenological growth stages of the persimmon tree (Diospyros kaki).
- Author
-
GARCÍA-CARBONELL, S, YAGÜE, B, BLEIHOLDER, H, HACK, H, MEIER, U, and AGUSTÍ, M
- Published
- 2002
- Full Text
- View/download PDF
14. Veinticinco números, veinticinco, de marcoELE (con regalito incluido)
- Author
-
Tolosa Montesinos, Juan and Yagüe Barredo, Agustín
- Subjects
Language and Literature - Abstract
Editorial
- Published
- 2017
15. ¿DidácTICa se escribe con TIC? reflexiones sobre las TIC en el aula de ELE
- Author
-
Yagüe Barredo, Agustín
- Subjects
ELE ,TIC ,didáctica ,SFL ,ICT ,didactics ,Language and Literature - Abstract
El presente texto, revisado y actualizado, fue presentado como desarrollo de la conferencia inaugural del IV Congreso Internacional del Español: Innovación, tecnología y comunicación en español (Salamanca, julio de 2016) para ser publicado en las Actas de dicho encuentro. Transcurrido casi un año sin que tales actas hayan sido publicadas, se comparten aquí aquellos contenidos, que reflexionan, de forma muy genérica, sobre el papel de las nuevas tecnologías en el aula de español lengua extranjera.
- Published
- 2017
16. Las gramáticas papELEs y eleFANTE: 'Behind the scenes'. Sin champiñones ni telarañas
- Author
-
Díaz Rodríguez, Lourdes and Yagüe Barredo, Agustín
- Subjects
gramática ,materiales didácticos ,procesos de aprendizaje ,Language and Literature - Abstract
El presente trabajo tiene como objetivo describir, razonar y justificar las decisiones didácticas que fundamentan las gramáticas papELEs y eleFANTE. Se pretende que el lector disponga de criterios para analizar estas obras (y, con ellos, también otras gramáticas); conocer, por consiguiente, algunos de los medios implicados en una eventual implantación en el aula (o como material de estudio); y, tal vez, apropiarse de algunas de las pautas seguidas cuando confeccione y/o adapte materiales didácticos, preferentemente gramaticales. Como se verá, las decisiones didácticas que se relatan intervienen en todos y cada uno de los aspectos de las obras, desde la gráfica hasta los ejercicios pasando por un largo etcétera que incluye los contenidos, la formulación de las soluciones, los ejemplos, la metalengua, etc
- Published
- 2015
17. [Otosyphilis as the cause of skew deviation and benign paroxysmal positional vertigo]
- Author
-
Casas-Limón J, Cm, Ordás-Bandera, Ja, Matías-Guiu, Barahona-Hernando R, Abarrategui-Yagüe B, García-Ramos R, and JESÚS PORTA-ETESSAM
18. Community-Onset Bloodstream and Other Infections, Caused by Carbapenemase-Producing Enterobacteriaceae: Epidemiological, Microbiological, and Clinical Features
- Author
-
Jr, Paño-Pardo, López Quintana B, Lázaro Perona F, Ruiz Carrascoso G, Mp, Romero-Gómez, Loeches Yagüe B, Díaz-Pollán B, Martínez-Virto A, Jesus Mingorance, García Rodríguez J, Jr, Arribas, and Gómez-Gil R
19. Examinando exámenes. Consideraciones acerca de las pruebas de medición en ELE
- Author
-
Yagüe Barredo, Agustín
- Subjects
exámenes ,measurement ,medición ,Spanish as a Foreign Language ,Español lengua extranjera ,testing ,Language and Literature - Abstract
El objetivo de este artículo es reflexionar acerca del concepto y el diseño de exámenes de español como lengua extranjera. Con criterios empíricos se subrayan las limitaciones técnicas de las pruebas y la pobreza de información que ofrecen a docentes y a candidatos sobre su actuación. El trabajo propone algunas alternativas que deben ser refrendadas en situaciones de aula.
- Published
- 2010
20. La participación de la mujer en el mambeadero en contexto urbano.
- Author
-
Yagüe, B.
- Abstract
Para muchos grupos indígenas amazónicos, el mambeadero es un espacio masculino por excelencia. El mambe es esencial para el proceso de conocimiento y curación, que en el mambeadero adquiere también una función ritual. En este espacio nocturno, se discuten cuestiones cotidianas de la comunidad, temas políticos y se realizan curaciones. Entre estos grupos indígenas, sólo los hombres p reparan el mambe, y sólo ellos y las mujeres ancianas mambean, algo que viene determinado desde el mito de origen. Sin embargo, la mujer está presente en el mambeadero, con la caguana y con su presencia, no en el semicírculo, pero sí alrededor, en el fogón o en la hamaca, escuchando o aprendiendo. A pesar de esto, el papel de la m ujer en estos espacios no recibe mucha importancia en el ámbito académico. Este trabajo abordó el cómo la mujer se ha ido abriendo espacio y participando de manera más activa en el contexto urbano de la ciudad de Leticia. Es un proceso con tensiones: malestares y conflictos, acompañado de aprendizaje para indígenas y no indígenas que entablan diálogo con estos grupos que en Leticia ya están organizados. Desde la perspectiva de algunos de sus actores (hombres y mujeres), se analizando la participación de la mujer, momentos, temáticas, dificultades, resistencias y logros construidos, en discusión con las prácticas culturales tradicionales que suelen resistirse a este tipo de transformaciones en las relaciones entre los géneros. Dentro de los hallazgos está la manera como la mujer indígena se hace presente y participa de los espacios políticos alrededor del mambeadero, y el papel central que tiene la mujer indígena en la venta del mambe en este espacio. [ABSTRACT FROM AUTHOR]
- Published
- 2014
21. ICO-ICS Praxis para el tratamiento médico y con irradiación de cáncer colorrectal
- Author
-
Berenguer Frances, Miguel Angel, Canals-Subirats, Eugeni, Caro-Gallarín, Mònica, Carreras Soler, Maria Josep, Elez Fernandez, Mª Elena, Garcia Rodriguez, Ariadna, Guerra-Prió, Silvia, Hernández-Yagüe, Xavier, Legido-Díaz, Raquel, Lezcano-Rubio, Clara, Losa-Gaspà, Ferrran, Mangues-Bafalluy, Irene, Manzano, Jose Luis, Mira-Flores, Moisés J., Navalpotro, Begoña, Emilce-Ramos, Analía, Salud-Salvia, Antonieta, Sanchez-Migallón-Montull, José M., Santos-Vivas, Cristina, Capdevila Castillon, Jaume, [Berenguer Francés MA] Servei d’Oncologia Radioteràpica, Institut Català d’Oncologia (ICO) L’Hospitalet, Generalitat de Catalunya, L’Hospitalet de Llobregat, Spain. [Canals-Subirats E] Servei d’Oncologia Radioteràpica, Institut Català d’Oncologia (ICO) Girona, Generalitat de Catalunya, Girona, Spain. [Capdevila Castillon J] Servei d’Oncologia Mèdica, Hospital Universitari Vall d’Hebron, Institut Català de la Salut (ICS), Generalitat de Catalunya, Barcelona, Spain. Vall d’Hebron Institut d’Oncologia (VHIO), Generalitat de Catalunya, Barcelona, Spain. [Caro-Gallarín M] Servei d’Oncologia Radioteràpica, Institut Català d’Oncologia (ICO) Badalona, Generalitat de Catalunya, Badalona, Spain. [Carreras-Soler MJ] Servei de Farmàcia, Hospital Universitari Vall d’Hebron, Institut Català de la Salut (ICS), Generalitat de Catalunya, Barcelona, Spain. Vall d'Hebron Institut de Recerca, Generalitat de Catalunya, Barcelona, Spain. [Élez Fernández E, García Rodríguez A] Servei d’Oncologia Mèdica, Hospital Universitari Vall d’Hebron, Institut Català de la Salut (ICS), Generalitat de Catalunya, Barcelona, Spain. Vall d’Hebron Institut d’Oncologia (VHIO), Generalitat de Catalunya, Barcelona, Spain. [Guerra-Prió S] Servei de Farmàcia, Institut Català d’Oncologia (ICO) Girona, Generalitat de Catalunya, Girona, Spain. Universitat de Girona, Girona, Spain. [Hernández-Yagüe X] Servei d’Oncologia Mèdica, Institut Català d’Oncologia (ICO) Girona, Generalitat de Catalunya, Girona, Spain. [Legido-Díaz R, Losa-Gaspà F] Servei d’Oncologia Mèdica, Institut Català d’Oncologia (ICO) L’Hospitalet, Generalitat de Catalunya, L’Hospitalet de Llobregat, Spain. [Lezcano-Rubio C] Servei de Farmàcia, Institut Català d’Oncologia (ICO) Badalona, Generalitat de Catalunya, Badalona, Spain. [Mangues-Bafalluy I] Servei de Farmàcia, Hospital Universitari Arnau de Vilanova, Institut Català de la Salut (ICS), Generalitat de Catalunya, Lleida, Spain. [Manzano-Mozo JL] Servei d’Oncologia Mèdica, Institut Català d’Oncologia (ICO) Badalona, Generalitat de Catalunya, Badalona, Spain. [Mira-Flores MJ] Servei d’Oncologia Radioteràpica, Hospital Universitari Arnau de Vilanova, Institut Català de la Salut (ICS), Generalitat de Catalunya, Lleida, Spain. [Navalpotro-Yagüe B] Servei d’Oncologia Radioteràpica, Hospital Universitari Vall d’Hebron, Institut Català de la Salut (ICS), Generalitat de Catalunya, Barcelona, Spain. Vall d’Hebron Institut d’Oncologia (VHIO), Generalitat de Catalunya, Barcelona, Spain. [Emilce-Ramos A] Unitat de Suport Nutricional, Hospital Universitari Germans Trias i Pujol, Institut Català de la Salut (ICS), Generalitat de Catalunya, Badalona, Spain. [Salud-Salvia A] Servei d’Oncologia Mèdica, Hospital Universitari Arnau de Vilanova, Institut Català de la Salut (ICS), Generalitat de Catalunya, Lleida, Spain. [Sánchez-Migallón-Montull JM] Unitat de Dietètica i Nutrició, Institut Català d’Oncologia (ICO) Badalona, Generalitat de Catalunya, Badalona, Spain. [Santos-Vivas C] Servei d’Oncologia Mèdica, Institut Català d’Oncologia (ICO) L’Hospitalet, Generalitat de Catalunya, L’Hospitalet de Llobregat, Spain, and Institut Català de la Salut
- Subjects
Neoplasms::Neoplasms by Site::Digestive System Neoplasms::Gastrointestinal Neoplasms::Intestinal Neoplasms::Colorectal Neoplasms [DISEASES] ,Other subheadings::Other subheadings::/radiotherapy [Other subheadings] ,Còlon - Càncer ,Càncer - Tractament ,Recte - Càncer ,Otros calificadores::Otros calificadores::/farmacoterapia [Otros calificadores] ,Otros calificadores::Otros calificadores::/radioterapia [Otros calificadores] ,Irradiació - Tractament ,Other subheadings::Other subheadings::/drug therapy [Other subheadings] ,neoplasias::neoplasias por localización::neoplasias del sistema digestivo::neoplasias gastrointestinales::neoplasias intestinales::neoplasias colorrectales [ENFERMEDADES] - Abstract
Tractament mèdic; Tractament amb irradiació; Còlon; Recte; Càncer Medical treatment; Irradiation treatment; Colon; Rectum; Cancer Tratamiento médico; Tratamiento con irradiación; Colon; Recto; Cáncer El càncer de còlon i recte (CCR) és el més freqüent a Catalunya segons dades del Pla director d’oncologia estimades per a 2017. La incidència del CCR és superior en homes, amb un increment anual de l'1,3% en els homes i el 0,5% en les dones des de 1994. A Espanya, segons l’informe de la SEOM, que recull dades de la REDECAN, posiciona el CCR com un dels més freqüents i probables de diagnosticar el 2019, amb 44.937 nous casos. Segons les dades dels registres de GLOBOCAN 2018, el CCR és el segon càncer amb més incidència a Europa. La incidència distribuïda per sexes és del 16,7% en homes i del 13,3% en dones. Els objectius d'aquesta guia són: -Desenvolupar, difondre, implementar i avaluar resultats de la ICO-ICSPraxi de càncer colorectal. -Disminuir la variabilitat terapèutica entre els pacients tractats als diferents centres d'aquesta institució. -Implementar els resultats de la terapèutica en els pacients amb adenocarcinoma de pàncrees tractats d'acord amb les recomanacions d'aquesta guia.
- Published
- 2020
22. ICO-ICS Praxi per al tractament mèdic i amb irradiació de càncer gàstric i d'unió esofagogàstrica
- Author
-
Alsina Maqueda, Maria, Boladeras Inglada, Anna M., Bugès Sanchez, Cristina, Calvo-Campos, Mariona, Canals-Subirats, Eugeni, Caro-Gallarín, Mònica, Creus Costas, Glòria, Fort-Casamartina, Eduard, Galán Guzmán, Maica, Gilabert-Sotoca, Marta, Guardeño Sánchez, Raquel, Guerra-Prió, Silvia, Hormigo Rubio, Glòria, Lezcano-Rubio, Clara, Mira-Flores, Moisés J., Navalpotro, Begoña, Serra-Solé, Òlbia, Tuset Der-Abrain, Noemí, Valdivia Vadell, Carolina, Virgili Casas, Núria, [Alsina Maqueda M] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Boladeras Inglada AM] Servei d’Oncologia Radioteràpica, Institut Català d’Oncologia (ICO) L’Hospitalet, Generalitat de Catalunya, L’Hospitalet de Llobregat, Spain. [Bugès Sanchez C]] Servei d’Oncologia Mèdica, Institut Català d’Oncologia (ICO) Badalona, Generalitat de Catalunya, Badalona, Spain. [Calvo Campos M, Hormigo Rubio G, Serra Solé O] Servei d’Oncologia Mèdica, Institut Català d’Oncologia (ICO) L’Hospitalet, Generalitat de Catalunya, L’Hospitalet de Llobregat, Spain. [Canals Subirats E] Servei d’Oncologia Radioteràpica, Institut Català d’Oncologia (ICO) Girona, Generalitat de Catalunya, Girona, Spain. [Caro Gallarín M] Servei d’Oncologia Radioteràpica, Institut Català d’Oncologia (ICO) Badalona, Generalitat de Catalunya, Badalona, Spain. [Creus Costa M, Virgili Casas N] Servei d’Endocrinologia i Nutrició, Unitat de Dietètica i Nutrició Clínica, Hospital Universitari de Bellvitge, Institut Català de la Salut (ICS), Generalitat de Catalunya, L’Hospitalet de Llobregat, Spain. [Font Casamartina E] Servei de Farmàcia, Institut Català d’Oncologia (ICO) L’Hospitalet, Generalitat de Catalunya, L’Hospitalet de Llobregat, Spain. [Galán Guzmán M] Servei d’Oncologia Mèdica, Institut Català d’Oncologia (ICO) L’Hospitalet, Generalitat de Catalunya, L’Hospitalet de Llobregat, Spain. [Gilabert Sotoca M] Servei de Farmàcia, Hospital Universitari Arnau de Vilanova, Institut Català de la Salut (ICS), Generalitat de Catalunya, Lleida, Spain. [Guardeño Sánchez R] Servei d’Oncologia Mèdica, Institut Català d’Oncologia (ICO) Girona, Generalitat de Catalunya, Girona, Spain. [Guerra Prió S] Servei de Farmàcia, Institut Català d’Oncologia (ICO) Girona, Generalitat de Catalunya, Girona, Spain. [Lezcano Rubio C] Servei de Farmàcia, Institut Català d’Oncologia (ICO) Badalona, Generalitat de Catalunya, Badalona, Spain. [Mira Flores MJ] Servei d’Oncologia Radioteràpica, Hospital Universitari Arnau de Vilanova, Institut Català de la Salut (ICS), Generalitat de Catalunya, Lleida, Spain. [Navalpotro Yagüe B] Servei d’Oncologia Radioteràpica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Tuset Der-Abrain N] Servei d’Oncologia Mèdica, Hospital Universitari Arnau de Vilanova, Institut Català de la Salut (ICS), Generalitat de Catalunya, Lleida, Spain. [Valdivia Vadell C] Servei de Farmàcia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall Hebron Institute of Oncology (VHIO), Barcelona, Spain, and Institut Català de la Salut
- Subjects
terapéutica::farmacoterapia [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS] ,Physical Phenomena::Radiation [PHENOMENA AND PROCESSES] ,Therapeutics::Drug Therapy [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT] ,neoplasias::neoplasias por localización::neoplasias del sistema digestivo::neoplasias gastrointestinales::neoplasias gástricas [ENFERMEDADES] ,Esòfag - Càncer ,Estómac - Càncer ,neoplasias::neoplasias por localización::neoplasias del sistema digestivo::neoplasias gastrointestinales::neoplasias del esófago [ENFERMEDADES] ,Neoplasms::Neoplasms by Site::Digestive System Neoplasms::Gastrointestinal Neoplasms::Stomach Neoplasms [DISEASES] ,Digestive System::Gastrointestinal Tract::Upper Gastrointestinal Tract::Esophagus::Esophagogastric Junction [ANATOMY] ,sistema digestivo::tracto gastrointestinal::tracto gastrointestinal superior::esófago::unión esofagogástrica [ANATOMÍA] ,fenómenos físicos::radiación [FENÓMENOS Y PROCESOS] ,Irradiació - Tractament ,Neoplasms::Neoplasms by Site::Digestive System Neoplasms::Gastrointestinal Neoplasms::Esophageal Neoplasms [DISEASES] - Abstract
Tractament mèdic; Tractament amb irradiació; Càncer de la unió esofagogàstrica Tratamiento médico; Tratamiento con irradiación; Cáncer de la unión esofagogástrica Medical treatment; Irradiation treatment; Esophagogastric union cancer El càncer gàstric (CG) és actualment el vuitè tipus de càncer més prevalent a la Unió Europea on, segons les estimacions, el 2018 es calculen 80.211 casos diagnosticats en ambdós sexes amb una taxa estimada d'incidència estandarditzada per edat de 6,4 casos per cada 100.000 habitants. En el cas d'Espanya, segons dades d'incidència i mortalitat del projecte GLOBOCAN i de l'Observatori Europeu del Càncer, se situa en novè lloc, després del càncer de bufeta i el càncer uterí, pel que fa a freqüència. Els objectius d'aquesta guia són: Desenvolupar, difondre, implementar i avaluar resultats de l'ICO-ICSPraxi de càncer gàstric i d'unió esofagogàstrica. Disminuir la variabilitat terapèutica entre els pacients tractats als diferents centres d'aquesta institució. Implementar els resultats de la terapèutica en els pacients amb càncer gàstric i d'unió esofagogàstrica tractats d'acord amb les recomanacions d'aquesta guia. El cáncer gástrico (CG) es actualmente el octavo tipo de cáncer más prevalente en la Unión Europea donde, según las estimaciones, el 2018 se calculan 80.211 casos diagnosticados en ambos sexos con una tasa estimada de incidencia estandarizada por edad de 6,4 casos por cada 100.000 habitantes. En el caso de España, según datos de incidencia y mortalidad del proyecto GLOBOCAN y del Observatorio Europeo del Cáncer, se sitúa en noveno lugar, después del cáncer de vejiga y el cáncer uterino, en cuanto a frecuencia. Los objetivos de esta guía son: Desarrollar, difundir, implementar y evaluar resultados del ICO-ICSPraxi de cáncer gástrico y de unión esofagogástrica. Disminuir la variabilidad terapéutica entre los pacientes tratados en los diferentes centros de esta institución. Implementar los resultados de la terapéutica en los pacientes con cáncer gástrico y de unión esofagogástrica tratados de acuerdo con las recomendaciones de esta guía. Gastric cancer (GC) is currently the eighth most prevalent type of cancer in the European Union where, according to estimates, 80,211 cases diagnosed in both sexes are estimated at an estimated rate of incidence standardized by age of 6.4 cases per 100,000 people. In the case of Spain, according to the incidence and mortality data of the GLOBOCAN project and the European Cancer Observatory, it is placed ninth, after bladder cancer and uterine cancer, as it happens frequently. The objectives of this guide are: Developing, disseminating, implementing and evaluating the results of the ICO-ICSPraxi of gastric cancer and esophagogastric binding. Decrease the therapeutic variability between patients treated at the different centers of this institution. Implement the results of therapeutic treatment in patients with gastric cancer and esphagogastric binding treated in accordance with the recommendations of this guide.
- Published
- 2019
23. ICO-ICS Praxi per al tractament mèdic i amb irradiació de l'adenocarcinoma de pàncrees
- Author
-
Arribas Garcia, Lorena, Berenguer Frances, Miguel Angel, Calvo-Campos, Mariona, Canals-Subirats, Eugeni, Caro-Gallarín, Mònica, Carreras Soler, Maria Josep, Carrizo-Ibarra, Maria V., Garcia Velasco, Adelaida, Gasol Cudos, Ariadna, Guerra-Prió, Silvia, Laquente, Berta, Layos-Romero, Laura, Lezcano-Rubio, Clara, Macarulla Mercadé, Teresa, Navalpotro, Begoña, Peiró, Inmaculada, Sánchez-López, Cristina, Serra-Solé, Òlbia, Gilabert-Sotoca, Marta, Verdaguer Mata, Helena, Burgos Peláez, Rosa, [Arribas-Hortigüela L, Peiró-Martínez I] Unitat Funcional de Nutrició Clínica, Institut Català d’Oncologia (ICO) L’Hospitalet, Generalitat de Catalunya, L’Hospitalet de Llobregat, Spain. [Berenguer-Francès MA] Servei d’Oncologia Radioteràpica, Institut Català d’Oncologia (ICO) L’Hospitalet, Generalitat de Catalunya, L’Hospitalet de Llobregat, Spain. [Burgos R] Unitat de Suport Nutricional, Hospital Universitari Vall d’Hebron, Institut Català de la Salut (ICS), Generalitat de Catalunya, Barcelona, Spain. Vall d'Hebron Institut de Recerca, Generalitat de Catalunya, Barcelona, Spain. [Calvo-Campos M, Sánchez-López C, Serra-Solé O] Servei d’Oncologia Mèdica, Institut Català d’Oncologia (ICO) L’Hospitalet, Generalitat de Catalunya, L’Hospitalet de Llobregat, Spain. [Canals-Subirats E] Servei d’Oncologia Radioteràpica, Institut Català d’Oncologia (ICO) Girona, Generalitat de Catalunya, Girona, Spain. [Caro-Gallarín M] Servei d’Oncologia Radioteràpica, Institut Català d’Oncologia (ICO) Badalona, Generalitat de Catalunya, Badalona, Spain. [Carreras-Soler MJ] Servei de Farmàcia, Hospital Universitari Vall d’Hebron, Institut Català de la Salut (ICS), Generalitat de Catalunya, Barcelona, Spain. Vall d'Hebron Institut de Recerca, Generalitat de Catalunya, Barcelona, Spain. [Carrizo-Ibarra MV] Servei d’Oncologia Radioteràpica, Hospital Universitari Arnau de Vilanova, Institut Català de la Salut (ICS), Generalitat de Catalunya, Lleida, Spain. [García-Velasco A] Servei d’Oncologia Mèdica, Institut Català d’Oncologia (ICO) Girona, Generalitat de Catalunya, Girona, Spain. Universitat de Girona, Girona, Spain. Universidad Complutense de Madrid, Madrid, Spain. [Gasol-Cudos A] Servei d’Oncologia Mèdica, Hospital Universitari Arnau de Vilanova, Institut Català de la Salut (ICS), Generalitat de Catalunya, Lleida, Spain. Universitat de Lleida, Lleida, Spain. [Guerra-Prió S] Servei de Farmàcia, Institut Català d’Oncologia (ICO) Girona, Generalitat de Catalunya, Girona, Spain. [Laquente-Sáez B] Servei d’Oncologia Mèdica, Institut Català d’Oncologia (ICO) L’Hospitalet, Generalitat de Catalunya, L’Hospitalet de Llobregat, Spain. Universitat de Barcelona, Barcelona, Spain. Hospital del Mar, Parc de Salut Mar, Generalitat de Catalunya, Barcelona, Spain. [Layos-Romero L] Servei de Farmàcia, Institut Català d’Oncologia (ICO) Badalona, Generalitat de Catalunya, Badalona, Spain. [Lezcano-Rubio C] Servei d’Oncologia Radioteràpica, Institut Català d’Oncologia (ICO) Badalona, Generalitat de Catalunya, Badalona, Spain. [Macarulla-Mercadé T] Servei d’Oncologia Mèdica, Hospital Universitari Vall d’Hebron, Institut Català de la Salut (ICS), Generalitat de Catalunya, Barcelona, Spain. Vall d’Hebron Institut d’Oncologia (VHIO), Generalitat de Catalunya, Barcelona, Spain. [Navalpotro-Yagüe B] Servei d’Oncologia Radioteràpica, Hospital Universitari Vall d’Hebron, Institut Català de la Salut (ICS), Generalitat de Catalunya, Barcelona, Spain. Vall d’Hebron Institut d’Oncologia (VHIO), Generalitat de Catalunya, Barcelona, Spain. Universidad Autónoma de Madrid, Madrid, Spain. [Gilabert-Sotoca M] Servei de Farmàcia, Hospital Universitari Arnau de Vilanova, Institut Català de la Salut (ICS), Generalitat de Catalunya, Lleida, Spain. [Verdaguer-Mata H] Servei d’Oncologia Mèdica, Hospital Universitari Vall d’Hebron, Institut Català de la Salut (ICS), Generalitat de Catalunya, Barcelona, Spain. Vall d’Hebron Institut d’Oncologia (VHIO), Generalitat de Catalunya, Barcelona, Spain. Institut Català d’Oncologia (ICO) L’Hospitalet, Generalitat de Catalunya, L’Hospitalet de Llobregat, Spain., and Institut Català de la Salut
- Subjects
Neoplasms::Neoplasms by Site::Digestive System Neoplasms::Pancreatic Neoplasms [DISEASES] ,Physical Phenomena::Radiation [PHENOMENA AND PROCESSES] ,Pàncrees - Càncer ,Neoplasms::Neoplasms by Histologic Type::Neoplasms, Glandular and Epithelial::Carcinoma::Adenocarcinoma [DISEASES] ,neoplasias::neoplasias por tipo histológico::neoplasias glandulares y epiteliales::carcinoma::adenocarcinoma [ENFERMEDADES] ,Other subheadings::/therapy [Other subheadings] ,fenómenos físicos::radiación [FENÓMENOS Y PROCESOS] ,Adenocarcinoma ,Irradiació - Tractament ,neoplasias::neoplasias por localización::neoplasias del sistema digestivo::neoplasias pancreáticas [ENFERMEDADES] ,Otros calificadores::/terapia [Otros calificadores] - Abstract
Tractament mèdic; Tractament amb irradiació; Adenocarcinoma; Pàncrees; Càncer Tratamiento médico; Tratamiento con irradiación; Adenocarcinoma; Páncreas; Cáncer Medical treatment; Irradiation treatment; Adenocarcinoma; Pancreas; Cancer El càncer de pàncrees se situa com la tercera causa més freqüent de càncer en la forma d'adenocarcinoma ductal pancreàtic. És un dels càncers més agressius i amb un percentatge més baix de curació. Els objectius d'aquesta guia són: -Desenvolupar, difondre, implementar i avaluar resultats de la ICO-ICSPraxi de càncer de pàncrees. -Disminuir la variabilitat terapèutica entre els pacients tractats als diferents centres d'aquesta institució. -Implementar els resultats de la terapèutica en els pacients amb adenocarcinoma de pàncrees tractats d'acord amb les recomanacions d'aquesta guia.
- Published
- 2018
24. Reprogramming tumor-associated macrophages with lipid nanosystems reduces PDAC tumor burden and liver metastasis.
- Author
-
Palencia-Campos A, Ruiz-Cañas L, Abal-Sanisidro M, López-Gil JC, Batres-Ramos S, Saraiva SM, Yagüe B, Navarro D, Alcalá S, Rubiolo JA, Bidan N, Sánchez L, Mura S, Hermann PC, de la Fuente M, and Sainz B
- Subjects
- Animals, Mice, Cell Line, Tumor, Humans, Tumor Microenvironment drug effects, Tumor Burden drug effects, Nanoparticles chemistry, Lipids chemistry, Vitamin E pharmacology, Vitamin E chemistry, Emulsions chemistry, Tumor-Associated Macrophages drug effects, Mice, Inbred C57BL, Liver Neoplasms drug therapy, Liver Neoplasms secondary, Pancreatic Neoplasms drug therapy, Pancreatic Neoplasms pathology, Carcinoma, Pancreatic Ductal drug therapy, Carcinoma, Pancreatic Ductal pathology
- Abstract
Background: Pancreatic ductal adenocarcinoma (PDAC) requires innovative therapeutic strategies to counteract its progression and metastatic potential. Since the majority of patients are diagnosed with advanced metastatic disease, treatment strategies targeting not only the primary tumor but also metastatic lesions are needed. Tumor-Associated Macrophages (TAMs) have emerged as central players, significantly influencing PDAC progression and metastasis. Our objective was to validate an innovative therapeutic strategy involving the reprogramming of TAMs using lipid nanosystems to prevent the formation of a pro-metastatic microenvironment in the liver., Results: In vitro results demonstrate that M2-polarized macrophages lose their M2-phenotype following treatment with lipid nanoemulsions composed of vitamin E and sphingomyelin (VitE:SM), transitioning to an M0/M1 state. Specifically, VitE:SM nanoemulsion treatment decreased the expression of macrophage M2 markers such as Arg1 and Egr2, while M1 markers such as Cd86, Il-1b and Il-12b increased. Additionally, the TGF-βR1 inhibitor Galunisertib (LY2157299) was loaded into VitE:SM nanoemulsions and delivered to C57BL/6 mice orthotopically injected with KPC PDAC tumor cells. Treated mice showed diminished primary tumor growth and reduced TAM infiltration in the liver. Moreover, we observed a decrease in liver metastasis with the nanoemulsion treatment in an intrasplenic model of PDAC liver metastasis. Finally, we validated the translatability of our VitE:SM nanosystem therapy in a human cell-based 3D co-culture model in vivo, underscoring the pivotal role of macrophages in the nanosystem's therapeutic effect in the context of human PDAC metastasis., Conclusions: The demonstrated effectiveness and safety of our nanosystem therapy highlights a promising therapeutic approach for PDAC, showcasing its potential in reprogramming TAMs and mitigating the occurrence of liver metastasis., Competing Interests: Declarations. Ethics approval and consent to participate: All in vivo procedures in mice were conducted in accordance with protocols approved by the local Animal Experimental Ethics Committee of the Instituto de Salud Carlos III (PA 34–2012) or the Use Committee for Animal Care from the Universidad Autónoma de Madrid (UAM) (Ref# CEI-25–587) and the Comunidad de Madrid (PROEX 335/14 or 294/19). Consent for publication: All authors agree with the publication Competing interests: The authors declare the following competing financial interest(s): M.d.l.F. is the co-founder and CEO of DIVERSA Technologies SL. The remaining authors declare no competing of interest., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
25. First Evidence of a HeartMate 3 Driveline Infection by Rhizopus Arrhizus: A Case Report.
- Author
-
Vila-García J, Marco Clement I, Poveda Pinedo ID, Loeches Yagüe B, Cid Menéndez A, and Moreno R
- Published
- 2024
- Full Text
- View/download PDF
26. Clinical features and prognosis of prosthetic valve endocarditis due to Staphylococcus aureus.
- Author
-
Diego-Yagüe I, Ramos-Martínez A, Muñoz P, Martínez-Sellés M, Machado M, de Alarcón A, Miró JM, Rodríguez-Gacía R, Gutierrez-Díez JF, Hidalgo-Tenorio C, Loeches-Yagüe B, and López-Azor JC
- Subjects
- Humans, Male, Female, Aged, Middle Aged, Prognosis, Spain epidemiology, Aged, 80 and over, Retrospective Studies, Risk Factors, Bacteremia microbiology, Bacteremia mortality, Staphylococcal Infections mortality, Staphylococcal Infections microbiology, Prosthesis-Related Infections microbiology, Prosthesis-Related Infections mortality, Staphylococcus aureus isolation & purification, Heart Valve Prosthesis adverse effects, Heart Valve Prosthesis microbiology, Endocarditis, Bacterial microbiology, Endocarditis, Bacterial mortality, Endocarditis, Bacterial surgery, Endocarditis, Bacterial diagnosis, Hospital Mortality
- Abstract
Purpose: Staphylococcus aureus prosthetic valve endocarditis (SAPVE) is a serious infection with high mortality. The main objective of this study was to identify factors associated with in-hospital mortality., Methods: From January 2008 to December 2021, consecutive patients from a Spanish cohort of infective endocarditis with a definitive diagnosis of SAPVE were analyzed., Results: During the study period, 219 cases of definitive SAPVE were diagnosed, which accounted for 16.7% of a total of 1309 cases of definitive prosthetic valve endocarditis (PVE). Patients presented advanced age and marked comorbidity. There was a higher incidence of persistent bacteremia, septic shock, stroke, and acute kidney injury than in cases of PVE caused by other microorganisms. Methicillin resistance was not associated with differences in clinical presentation, echocardiographic findings, or mortality. Only 50.6% of the patients with surgical indications (88 patients) underwent surgery. Overall, in-hospital mortality was 47.9%. The variables associated with in-hospital mortality were age (OR:1.03, 95% CI: 1.00-1.05; p = 0.016), heart failure (OR:2.86, 95% CI: 1.53-5.32; p = 0.001), acute kidney injury (OR:2.42, 95%CI:1.28-4.58; p = 0.006), stroke (OR:3.53, 95%CI:1.79-6.96; p < 0.001) and surgery indicated but not performed (OR:2.01, 95%CI:1.06-3.8; p = 0.030). On the other hand, the performance of surgery per se in patients with SAPVE, regardless of whether there was a surgical indication according to the guidelines, was not associated with a reduction in in-hospital mortality., Conclusions: SAPVE is characterized by high mortality, which is more marked in patients who present a surgical indication but do not undergo surgery., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
27. Urease-powered nanobots for radionuclide bladder cancer therapy.
- Author
-
Simó C, Serra-Casablancas M, Hortelao AC, Di Carlo V, Guallar-Garrido S, Plaza-García S, Rabanal RM, Ramos-Cabrer P, Yagüe B, Aguado L, Bardia L, Tosi S, Gómez-Vallejo V, Martín A, Patiño T, Julián E, Colombelli J, Llop J, and Sánchez S
- Subjects
- Mice, Animals, Administration, Intravesical, Radioisotopes therapeutic use, Urease, Urinary Bladder Neoplasms diagnostic imaging, Urinary Bladder Neoplasms drug therapy
- Abstract
Bladder cancer treatment via intravesical drug administration achieves reasonable survival rates but suffers from low therapeutic efficacy. To address the latter, self-propelled nanoparticles or nanobots have been proposed, taking advantage of their enhanced diffusion and mixing capabilities in urine when compared with conventional drugs or passive nanoparticles. However, the translational capabilities of nanobots in treating bladder cancer are underexplored. Here, we tested radiolabelled mesoporous silica-based urease-powered nanobots in an orthotopic mouse model of bladder cancer. In vivo and ex vivo results demonstrated enhanced nanobot accumulation at the tumour site, with an eightfold increase revealed by positron emission tomography in vivo. Label-free optical contrast based on polarization-dependent scattered light-sheet microscopy of cleared bladders confirmed tumour penetration by nanobots ex vivo. Treating tumour-bearing mice with intravesically administered radio-iodinated nanobots for radionuclide therapy resulted in a tumour size reduction of about 90%, positioning nanobots as efficient delivery nanosystems for bladder cancer therapy., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
28. Increase of healthcare-onset Clostridioides difficile infection in adult population since SARS-CoV-2 pandemic: A retrospective cohort study in a tertiary care hospital from 2019 to 2022.
- Author
-
Maldonado-Barrueco A, Moreno-Ramos F, Díaz-Pollán B, Loeches-Yagüe B, Rico-Nieto A, García-Rodríguez J, and Ruiz-Carrascoso G
- Subjects
- Humans, Diarrhea epidemiology, Vancomycin administration & dosage, Spain epidemiology, Retrospective Studies, Incidence, Disease Outbreaks, Prevalence, Anti-Bacterial Agents administration & dosage, Risk, Pandemics statistics & numerical data, Infection Control statistics & numerical data, Meropenem administration & dosage, Middle Aged, Aged, Aged, 80 and over, Clostridioides difficile genetics, Clostridioides difficile isolation & purification, Clostridium Infections diagnosis, Clostridium Infections epidemiology, Clostridium Infections microbiology, COVID-19 epidemiology, Cross Infection diagnosis, Cross Infection epidemiology, Cross Infection microbiology, Tertiary Care Centers
- Abstract
Objectives: The aim was to assess the impact of the SARS-CoV-2 pandemic on the prevalence, relative incidence (RI), incidence density (ID), ratio of rate incidence (RRI), rate of incidence density (RID), and relative risks (RR) of healthcare-onset Clostridioides difficile infection (HO-CDI) as well as its correlation with the antibiotic consumption., Methods: Demographic and analytical data of adult patients exhibiting diarrhoea and testing positive for C. difficile were systematically collected from a tertiary care hospital in Madrid (Spain). The periods analysed included: prepandemic (P0), first pandemic-year (P1), and second pandemic-year (P2). We compared global prevalence, RI of HO-CDI per 1,000-admissions, ID of HO-CDI per 10,000-patients-days, RRI, RID, and RR. Antibiotic consumption was obtained by number of defined daily dose per 100 patient-days., Results: In P0, the prevalence of HO-CDI was 7.4% (IC95%: 6.2-8.7); in P1, it increased to 8.7% (IC95%: 7.4-10.1) (p = 0.2), and in P2, it continued to increase to 9.2% (IC95%: 8-10.6) (p < 0.05). During P1, the RRI was 1.5 and RID was 1.4. However, during P2 there was an increase in RRI to 1.6 and RID to 1.6. The RR also reflected the increase in HO-CDI: at P1, the probability of developing HO-CDI was 1.5 times (IC95%: 1.2-1.9) higher than P0, while at P2, this probability increased to 1.6 times (IC95%: 1.3-2.1). There was an increase in prevalence, RI, ID, RR, RRI, and RID during the two postpandemic periods respect to the prepandemic period. During P2, this increase was greater than the P1. Meropenem showed a statistically significant difference increased consumption (p < 0.05) during the pandemic period. Oral vancomycin HO-CDI treatment showed an increase during the period of study (p > 0.05)., Conclusions: Implementation of infection control measures during the SARS-CoV-2 pandemic did not appear to alleviate the burden of HO-CDI. The escalation in HO-CDI cases did not exhibit a correlation with overall antibiotic consumption, except for meropenem., Competing Interests: Declaration of competing interest The authors declare that they have no financial interests or personal relationships that could have influenced the work presented in this article. The authors received no external funding from any of the commercial companies for this study., (Copyright © 2024 Elsevier Ltd. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
29. Myocarditis by Toxoplasma gondii in an immunocompetent young man.
- Author
-
Loeches Yagüe B, Rico-Nieto A, Refoyo Salicio E, and Iniesta Manjavacas ÁM
- Subjects
- Male, Humans, Toxoplasma, Myocarditis diagnosis
- Published
- 2023
- Full Text
- View/download PDF
30. Bacteremia due to C. jejuni in kidney transplant patients. Is immediate post-transplant immunosuppression a risk factor?
- Author
-
Santos-Alonso C, González-García E, Ruíz-Carrascoso G, and Loeches-Yagüe B
- Subjects
- Humans, Immunosuppression Therapy adverse effects, Risk Factors, Bacteremia epidemiology, Bacteremia etiology, Kidney Transplantation adverse effects
- Published
- 2022
- Full Text
- View/download PDF
31. Iron Oxide Incorporated Conjugated Polymer Nanoparticles for Simultaneous Use in Magnetic Resonance and Fluorescent Imaging of Brain Tumors.
- Author
-
Arias-Ramos N, Ibarra LE, Serrano-Torres M, Yagüe B, Caverzán MD, Chesta CA, Palacios RE, and López-Larrubia P
- Abstract
Conjugated polymer nanoparticles (CPNs) have emerged as advanced polymeric nanoplatforms in biomedical applications by virtue of extraordinary properties including high fluorescence brightness, large absorption coefficients of one and two-photons, and excellent photostability and colloidal stability in water and physiological medium. In addition, low cytotoxicity, easy functionalization, and the ability to modify CPN photochemical properties by the incorporation of dopants, convert them into excellent theranostic agents with multifunctionality for imaging and treatment. In this work, CPNs were designed and synthesized by incorporating a metal oxide magnetic core (Fe
3 O4 and NiFe2 O4 nanoparticles, 5 nm) into their matrix during the nanoprecipitation method. This modification allowed the in vivo monitoring of nanoparticles in animal models using magnetic resonance imaging (MRI) and intravital fluorescence, techniques widely used for intracranial tumors evaluation. The modified CPNs were assessed in vivo in glioblastoma (GBM) bearing mice, both heterotopic and orthotopic developed models. Biodistribution studies were performed with MRI acquisitions and fluorescence images up to 24 h after the i.v. nanoparticles administration. The resulting IONP-doped CPNs were biocompatible in GBM tumor cells in vitro with an excellent cell incorporation depending on nanoparticle concentration exposure. IONP-doped CPNs were detected in tumor and excretory organs of the heterotopic GBM model after i.v. and i.t. injection. However, in the orthotopic GBM model, the size of the nanoparticles is probably hindering a higher effect on intratumorally T2-weighted images (T2 WI) signals and T2 values. The photodynamic therapy (PDT)-cytotoxicity of CPNs was not either affected by the IONPs incorporation into the nanoparticles.- Published
- 2021
- Full Text
- View/download PDF
32. Bacteremia due to C. jejuni in kidney transplant patients. Is immediate post-transplant immunosuppression a risk factor?
- Author
-
Santos-Alonso C, González-García E, Ruíz-Carrascoso G, and Loeches-Yagüe B
- Published
- 2021
- Full Text
- View/download PDF
33. Community-Onset Bloodstream and Other Infections, Caused by Carbapenemase-Producing Enterobacteriaceae : Epidemiological, Microbiological, and Clinical Features.
- Author
-
Paño-Pardo JR, López Quintana B, Lázaro Perona F, Ruiz Carrascoso G, Romero-Gómez MP, Loeches Yagüe B, Díaz-Pollán B, Martínez-Virto A, Mingorance J, García Rodríguez J, Arribas JR, and Gómez-Gil R
- Abstract
Background. Because most infections caused by carbapenemase-producing Enterobacteriaceae (CPE) begin during hospitalization, there are limited data about community-onset (CO) infections caused by CPE. Our aim is to describe the frequency of CO infections caused by CPE as well as the clinical features of CO bloodstream infections (CO-BSIs). Methods. This study includes retrospective case series of CO infections caused by CPE in a tertiary hospital from January 2010 to July 2014. Any clinical sample with a positive culture for CPE that had been ordered by primary care doctors or by doctors at the emergency room (ER) were classified as CO. Epidemiological and microbiological features of CO cases were assessed as were clinical features of CO-BSIs. Results. Of 780 clinical samples with CPE, 180 were requested at the ER or by primary care doctors (22.9%), 150 of which were produced by Klebsiella pneumoniae (83.3%). The bla
OXA-48 gene was detected in 149 isolates (82.8%) followed by the blaVIM gene, 29 (16.1%). Sixty-one patients (33.9%) had a prior history of CPE infection/colonization. Thirty-four of the 119 (28.6%) patients without prior history of CPE infection/colonization did not fulfill Friedman criteria for healthcare-associated infections (HAIs). Considering previous hospitalization of up to 12 months as a criterion for defining HAI, only 16 (13.4%) cases were identified as community-acquired infections. The most frequent positive sample was urine (133 of 180; 73.9%). Twenty-one (11.7%) patients had a BSI, 9 of them secondary to urinary tract infections (42.9%). Thirty-day crude mortality among patients with BSI was 23.8% (5 of 21). Conclusions. Community-onset infections caused by CPE are an important subgroup of all CPE infections. The urinary tract is the main source. Bloodstream infections accounted for more than 10% of the cases.- Published
- 2016
- Full Text
- View/download PDF
34. [Otosyphilis as the cause of skew deviation and benign paroxysmal positional vertigo].
- Author
-
Casas-Limón J, Ordás-Bandera CM, Matías-Guiu JA, Barahona-Hernando R, Abarrategui-Yagüe B, García-Ramos R, and Porta-Etessam J
- Subjects
- Aged, Anti-Bacterial Agents therapeutic use, Benign Paroxysmal Positional Vertigo, Cerebellar Neoplasms diagnosis, Diagnosis, Differential, Diplopia etiology, Hearing Loss, Sensorineural etiology, Humans, Labyrinthitis diagnosis, Labyrinthitis drug therapy, Male, Neurosyphilis diagnosis, Neurosyphilis drug therapy, Penicillin G therapeutic use, Stroke diagnosis, Labyrinthitis complications, Neurosyphilis complications, Ocular Motility Disorders etiology, Vertigo etiology
- Published
- 2012
35. [Dysphonia due to oral methylprednisolone. An uncommon adverse side effect].
- Author
-
Loeches-Yagüe B and de Lorenzo-Cáceres A
- Subjects
- Administration, Oral, Aged, Glucocorticoids administration & dosage, Humans, Male, Methylprednisolone administration & dosage, Glucocorticoids adverse effects, Methylprednisolone adverse effects, Voice Disorders chemically induced
- Published
- 2006
- Full Text
- View/download PDF
36. Adjuvant treatment of locally-advanced head and neck tumours.
- Author
-
Reyes López V and Navalpotro Yagüe B
- Subjects
- Antineoplastic Agents therapeutic use, Carcinoma, Squamous Cell drug therapy, Carcinoma, Squamous Cell radiotherapy, Chemotherapy, Adjuvant methods, Combined Modality Therapy, Disease-Free Survival, Head and Neck Neoplasms drug therapy, Head and Neck Neoplasms radiotherapy, Humans, Postoperative Care methods, Treatment Outcome, Carcinoma, Squamous Cell therapy, Head and Neck Neoplasms therapy
- Abstract
Every year about 40,000 new patients are diagnosed as having squamous cell carcinoma of the head and neck (HNSCC) and nearly 60% of this population present with locally-advanced, but non-metastatic, disease. For many years, radiation therapy (RT) alone has been the standard non-surgical treatment for locally-advanced disease. Nevertheless, even the most effective RT regimens (the once-daily, hyperfractionation, or accelerated fractionation) show an improvement in local control rates of 50%-70% and disease-free survival rates of 30%-40%. These modest results have stimulated the search for novel strategies combining RT and chemotherapy. Several chemotherapeutic agents have been tested in combination with RT and cisplatin appears to be the most powerful agent in the treatment of locally-advanced head and neck tumours; as has been demonstrated in a large meta-analysis and, recently, in two multi-centred randomised trials. Based on these results, concurrent chemo-radiotherapy may be considered the standard adjuvant treatment for locally-advanced head and neck tumours.
- Published
- 2005
- Full Text
- View/download PDF
37. [Information leaflets for primary care patients].
- Author
-
Loeches Yagüe B and de Lorenzo-Cáceres Ascanio A
- Subjects
- Family Practice, Humans, Pamphlets, Patient Education as Topic methods, Primary Health Care
- Published
- 2004
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.